Abstract
We appreciate the comments by Dr Reiffel about our report1 from the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee Meeting, December 2007, which reviewed 2 development programs for the acute pharmacological conversion of atrial fibrillation. On the basis of his letter, we would like to clarify several points. The deliberations and recommendations of FDA advisory panels are focused on the development program under review and therefore do not serve as …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
